Plus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. đź“Š Erasca targets $550M for KRAS drugs: The biotech's public offering came after it shared a small …
Source: Endpoints News
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.